Online Education

22HT00053 – A School Nurse’s Guide to Bleeding Disorders: Hemophilia

May 27, 2022

5:00 PM Eastern, May 27, 2024
The estimated time to complete this activity is 45 minutes.

This online learning activity aims to enable the learner to develop basic knowledge and skills regarding etiology, inheritance, severity, and treatment of hemophilia, recognition of hemophilia symptoms, and use of strategies to promote a safe and positive learning environment.

The activity is designed for school nurses, nurse practitioners, and other school personnel who require basic knowledge and skill to effectively practice and teach in schools attended by a student with hemophilia. This involves debunking common myths that persist about hemophilia and replacing those myths with factual information concerning the etiology, inheritance, severity, and treatment of hemophilia. It includes information on identifying prevalent locations and symptoms of bleeding in hemophilia. Finally, the activity reviews strategies that may be implemented in the school setting to promote a safe and positive learning environment for the student with hemophilia.

This accredited continuing education activity is designed for nurses and nurse practitioners who practice in schools attended by a student with hemophilia. It may also be helpful to teachers, physical education and sports coaches, administrators, guidance counselors, and other educators and healthcare professionals needing an introduction to school related considerations in hemophilia.

At the conclusion of this activity, the participants should be better able to:

• Dispel common misconceptions about hemophilia
• Review basic information about the etiology, inheritance, and severity of hemophilia
• Identify prevalent locations and symptoms of joint and muscle bleeding in hemophilia
• Describe hemophilia treatment strategies and medications utilized and avoided in hemophilia management
• Discuss guidelines for participation in physical activity and sports by persons with hemophilia
• Integrate reasonable accommodations in the school setting to promote a safe and positive learning environment for the student with hemophilia
• Explain the role of the Hemophilia Treatment Center as a resource for support for schools attended by a student with hemophilia

In order to receive continuing education credits, you must complete these steps prior to the activity expiration date.

• Read the Disclosure Information found in the To Dos section.
• Complete the learning activity
• Complete the evaluation
• Complete the post-test with a score of 70% or better
• Upon successful completion of the post-test your certificate of completion will be available to print or save

In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Partners in Bleeding Disorders Education Program. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NURSES/NURSE PRACTITIONERS
The University of Nebraska Medical Center designates this activity for 0.75 ANCC contact hours. Nurses should only claim credit for the actual time spent participating in the activity.

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

If you have any questions about this activity, please contact Brooke Hernandez in Indianapolis, IN, 317-871-0011 ext. 813 or via email at bhernandez@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High-speed internet connection
• Internet browser (current version) – Firefox, Safari, Chrome, or Explorer
  • Cookies and JavaScript must be enabled in the browser

21HT50947 - Best Transition Practices for Adolescents and Young Adults with Sickle Cell Disease

July 8, 2021

5:00 PM Eastern, July 8, 2022
The estimated time to complete this activity is 30 minutes.

The purpose of this activity is to enable the learners to increase knowledge of the care needs of adolescents and young adults (AYAs), the emotional and social development of adolescence, the six core elements of a transition program, and the emotional/social milestones that should be addressed in a transition program for AYAs living with sickle cell disease (SCD).

This online learning activity is focused on improving health outcomes for adolescents and young adults (AYAs) with sickle cell disease (SCD) by improving transition programs and services available for these individuals. The activity will review the emotional and social development of adolescence. It will also discuss the health risks associated with transition among AYAs living with SCD. The module differentiates the pediatric and adult models of care, and examines the six core elements of transition programs, as derived from www.GotTransition.org. Finally, the activity will discuss the medical, social, and educational milestones that should be addressed in transition programs for AYAs with SCD.

This enduring material is intended for physicians, physician assistants, nurses, nurse practitioners, and other health care providers who treat adolescents and young adults with sickle cell disease and wish to improve outcomes associated with the transition from pediatric to adult care for these patients.

At the conclusion of this enduring material, the participants should be better able to:

• Review emotional and social development of adolescence
• Identify health risks associated with transition among adolescents and young adults (AYAs) living with sickle cell disease (SCD)
• Differentiate pediatric and adult models of sickle cell care
• Discuss the six core elements of a transition program
• Describe the medical, social, and educational milestones that should be addressed in a transition program for AYAs living with SCD

• Emily Riehm Meier, MD, MSHS

In order to receive continuing education credits, you must complete these steps prior to the activity expiration date.

• Read the Disclosure Information found in the To Dos section.
• Complete the learning activity
• Complete the evaluation
• Complete the post-test with a score of 70% or better
• Upon successful completion of the post-test your certificate of completion will be available to print or save

In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Indiana Hemophilia & Thrombosis Center. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Nebraska Medical Center designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The University of Nebraska Medical Center designates this activity for 0.5 ANCC contact hours. Nurses should only claim credit for the actual time spent participating in the activity.

No commercial support was received for this activity.

If you have any questions about this activity, please contact Brooke Hernandez in Indianapolis, IN, 317-871-0011 ext. 813 or via email at bhernandez@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High-speed internet connection
• Internet browser (current version) – Firefox, Safari, Chrome, or Explorer
  • Cookies and JavaScript must be enabled in the browser

21HT50948 - Comprehensive Care of Adolescents and Young Adults with Sickle Cell Disease

July 8, 2021

5:00 PM Eastern, July 8, 2022
The estimated time to complete this activity is 60 minutes.

The purpose of this activity is to enable the learner to gain knowledge necessary to better manage the comprehensive care of adolescents and young adults with sickle cell disease, with the aim of improving health outcomes among these individuals.

This online educational activity covers screening tests that are important in the care of adolescent and young adults (AYAs) with sickle cell disease and the most commonly used medications in this patient group. It also covers reproductive health considerations of AYAs with sickle cell disease, including the need for contraception, the existing knowledge gaps, and the epidemiology and management of priapism. Finally, the activity addresses practical pain management strategies in AYAs with sickle cell disease.

This enduring material is intended for physicians, physician assistants, nurses, nurse practitioners, and other health care providers who treat persons with sickle cell disease (SCD) and wish to improve comprehensive care services provided to adolescents and young adults (AYAs) with sickle cell disease.

At the conclusion of this enduring material, the participants should be better able to:

• Interpret the screening tests needed for adolescents and young adults (AYAs) with sickle cell disease (SCD)
• Review common complications of SCD in AYAs with this condition
• Describe the contraceptive choices in girls and women with SCD
• Review management of priapism, both ischemic and stuttering, in males with SCD
• Discuss practical strategies in pain management for AYAs with SCD
• Identify disease-modifying therapies that are FDA-approved for the treatment of SCD
• Describe the primary gap in knowledge of reproductive issues for patients with SCD receiving hydroxyurea therapy

• Emily Riehm Meier, MD, MSHS

In order to receive continuing education credits, you must complete these steps prior to the activity expiration date.

• Read the Disclosure Information found in the To Dos section.
• Complete the learning activity
• Complete the evaluation
• Complete the post-test with a score of 70% or better
• Upon successful completion of the post-test your certificate of completion will be available to print or save

In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Indiana Hemophilia & Thrombosis Center. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Nebraska Medical Center designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The University of Nebraska Medical Center designates this activity for 1.0 ANCC contact hour. This activity is provided for 0.25 contact hours related to pharmacotherapeutic content. Nurses should only claim credit for the actual time spent participating in the activity.

No commercial support was received for this activity.

If you have any questions about this activity, please contact Brooke Hernandez in Indianapolis, IN, 317-871-0011 ext. 813 or via email at bhernandez@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High-speed internet connection
• Internet browser (current version) – Firefox, Safari, Chrome, or Explorer
  • Cookies and JavaScript must be enabled in the browser

21HT50228 - Gene Therapy for Providers 101

October 26, 2021

5:00 PM Eastern, June 30, 2022
The estimated time to complete this activity is 45 minutes.

The purpose of this activity is to enable learners to develop basic knowledge of gene therapy for hemophilia, thereby enhancing learner competence to discuss gene therapy with patients who may benefit from this emerging treatment.

This learning activity provides basic education on hemophilia gene therapy, including the aims of gene therapy; the packaging, delivery, and activity of the replacement genes; and the means by which the replacement genes lead to production and/or availability of normal clotting factor in persons with hemophilia. The module will also review information that may be particularly important when discussing hemophilia gene therapy with patients, such as knowledgeable informed consent, outcomes data, and potential risks and benefits.

This enduring material is intended for multidisciplinary providers at hemophilia treatment centers, including nurses, physicians, pharmacists, physical therapists, social workers, and genetic counselors providing care to persons with hemophilia A and hemophilia B.

At the conclusion of this enduring material, the participants should be better able to:

• Describe a pathway to preparedness for gene therapy from education of the multidisciplinary healthcare team to clinical delivery
• Provide an overview of the goal of gene therapy for hemophilia
• Explain the elements of gene therapy (i.e. packaging, administration, mechanism of action)
• Define the profile of gene therapy candidates with FVIII deficiency and FIX deficiency
• Review known adverse effects from completed and ongoing clinical trials
• Articulate critical considerations for the multidisciplinary healthcare team in providing care for patients receiving gene therapy
• Discuss issues related to obtaining knowledgeable informed consent and counseling patients

• Steven Pipe, MD
• Shelley Crary, MD, MSCS

In order to receive continuing education credits, you must complete these steps prior to the activity expiration date.

• Read the Disclosure Information found in the To Dos section.
• Complete the learning activity
• Complete the evaluation
• Complete the post-test with a score of 70% or better
• Upon successful completion of the post-test your certificate of completion will be available to print or save

In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Indiana Hemophilia & Thrombosis Center. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIANS/PHYSICIAN ASSISTANTS
The University of Nebraska Medical Center designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PHARMACISTS (PharmDs/RPhs)
The University of Nebraska Medical Center designates this enduring activity for (ACPE UAN, JA0000319-9999-21-005-H01-P) 0.75 ACPE contact hours. Pharmacists should claim only the credit commensurate with the extent of their participation in the activity. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion.

NURSES/NURSE PRACTITIONERS
The University of Nebraska Medical Center designates this activity for 0.75 ANCC contact hours. Nurses should only claim credit for the actual time spent participating in the activity.

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc., and the National Hemophilia Foundation.

If you have any questions about this activity, please contact Brooke Hernandez in Indianapolis, IN, 317-871-0011 ext. 813 or via email at bhernandez@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High-speed internet connection
• Internet browser (current version) – Firefox, Safari, Chrome, or Explorer
  • Cookies and JavaScript must be enabled in the browser

21HT52379 - Gene Therapy for Providers 201

October 26, 2021

5:00 PM Eastern, June 30, 2022
The estimated time to complete this activity is 60 minutes.

The purpose of this activity is to enable HTC multidisciplinary staff and institutional stakeholders to gain knowledge on the steps necessary to prepare an institution to administer AAV-mediated gene therapy for hemophilia.

This learning activity is a process-oriented intermediate course that will guide HTC staff through the steps an institution must take to prepare to administer hemophilia gene therapy upon commercial availability of these products.

This enduring material is intended for HTC multidisciplinary staff (physicians, physician assistants, nurses, nurse practitioners, physical therapists, social workers, pharmacists, geneticists, genetic counselors, infusion room staff) and institutional stakeholders (e.g., HTC administrators and directors, clinic and pharmacy billing staff, insurance coordinators).

At the conclusion of this enduring material, the participants should be better able to:

• Identify patients who are eligible for AAV-mediated gene therapy
• Discuss key concepts involving education and shared decision-making for gene therapy
• Identify logistical/infrastructure requirements to procure, reconstitute and administer gene therapy at a dosing site
• Articulate the regional approach of preparing for gene therapy administration
• Distinguish the roles and responsibilities within the HTC team involved in the safety and efficacy assessments during short-and long-term monitoring before and after gene therapy
• Describe approaches to prevention, diagnosis, and treatment of vector-induced transaminitis after gene therapy

• Rebecca Kruse-Jarres, MD, MPH
• Ulrike Margret Reiss, MD
• Courtney Dawn Thornburg, MD, MS

In order to receive continuing education credits, you must complete these steps prior to the activity expiration date.

• Read the Disclosure Information found in the To Dos section.
• Complete the learning activity
• Complete the evaluation
• Complete the post-test with a score of 70% or better
• Upon successful completion of the post-test your certificate of completion will be available to print or save

In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Indiana Hemophilia & Thrombosis Center. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIANS/PHYSICIAN ASSISTANTS
The University of Nebraska Medical Center designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PHARMACISTS (PharmDs/RPhs)
The University of Nebraska Medical Center designates this enduring activity for (ACPE UAN, JA0000319-9999-21-006-H01-P) 1.0 ACPE contact hour. Pharmacists should claim only the credit commensurate with the extent of their participation in the activity. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion.

NURSES/NURSE PRACTITIONERS
The University of Nebraska Medical Center designates this activity for 1.0 ANCC contact hour. Nurses should only claim credit for the actual time spent participating in the activity.

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc., and the National Hemophilia Foundation.

If you have any questions about this activity, please contact Brooke Hernandez in Indianapolis, IN, 317-871-0011 ext. 813 or via email at bhernandez@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High-speed internet connection
• Internet browser (current version) – Firefox, Safari, Chrome, or Explorer
  • Cookies and JavaScript must be enabled in the browser

21HT52380 – Gene Therapy for Providers 301

October 26, 2021

5:00 PM Eastern, June 30, 2022
The estimated time to complete this activity is 60 minutes.

The purpose of this activity is to enable HTC multidisciplinary staff and hospital staff to support patients and their families as they consider hemophilia gene therapy, including education of patients and families on basic concepts in hemophilia gene therapy; administrative preparedness for providers; and short- and long-term care demands.

This learning activity is a process-oriented intermediate course that will guide HTC staff through the steps an institution must take to prepare to administer hemophilia gene therapy upon commercial availability of these products.

This enduring material is intended for physicians, physician assistants, nurses, nurse practitioners, physical therapists, social workers, pharmacists, and infusion room staff.

At the conclusion of this enduring material, the participants should be better able to:

• Discuss introductory concepts in hemophilia gene therapy
• Outline the process of preparing patients, hemophilia treatment centers, and hospital systems for the administration of gene therapy
• Explain the steps necessary for multidisciplinary team members to engage in shared patient-centered and population focused problem solving when procuring a hemophilia gene therapy product, preparing the product, and infusing the patient safely
• Discuss short term monitoring, specifically immediately after infusion and during the first three months of follow up
• Discuss long term monitoring, specifically from 3 to 24 months post infusion and > 24 months post infusion

• Doris V. Quon, MD
• Lindsey A. George, MD

In order to receive continuing education credits, you must complete these steps prior to the activity expiration date.

• Read the Disclosure Information found in the To Dos section.
• Complete the learning activity
• Complete the evaluation
• Complete the post-test with a score of 70% or better
• Upon successful completion of the post-test your certificate of completion will be available to print or save

In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Indiana Hemophilia & Thrombosis Center. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIANS/PHYSICIAN ASSISTANTS
The University of Nebraska Medical Center designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PHARMACISTS (PharmDs/RPhs)
The University of Nebraska Medical Center designates this enduring activity for (ACPE UAN, JA0000319-9999-21-007-H01-P) 1.0 ACPE contact hour. Pharmacists should claim only the credit commensurate with the extent of their participation in the activity. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion.

NURSES/NURSE PRACTITIONERS
The University of Nebraska Medical Center designates this activity for 1.0 ANCC contact hour. Nurses should only claim credit for the actual time spent participating in the activity.

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc., and the National Hemophilia Foundation.

If you have any questions about this activity, please contact Brooke Hernandez in Indianapolis, IN, 317-871-0011 ext. 813 or via email at bhernandez@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High-speed internet connection
• Internet browser (current version) – Firefox, Safari, Chrome, or Explorer
  • Cookies and JavaScript must be enabled in the browser

Hemophilia in Pictures

2005

The purpose of Hemophilia in Pictures is to provide basic knowledge about hemophilia through pictures and easy-to-understand information.

This online learning module covers a range of topics, including an introduction to hemophilia, assessing and managing bleeds, treatment of bleeds, staying healthy and preventing bleeds, and venipuncture and home therapy.

Hemophilia in Pictures is for hemophilia educators and people with hemophilia alike. The information is basic and is provided through pictures and easy-to-understand language, so it is accessible to anyone.

Hemophilia in Pictures has many goals. Please refer to the HIP Educators Guide to learn more about the educational goals for Educators as well as People with Hemophilia.

• Lara Oyesiku, Chair of the HIP Working Group and Nurse's Committee, England
• Martin Bedford, Educational Advisor, England
• Annie Gillham, Nurse Advisor, South Africa
• Dr. Peter Jones, Medical Advisor, England
• Kathy Mulder, Physiotherapy Advisor, Canada
• David Page, Educational Advisor, Canada
• Laurie Blackstock, WFH Education Officer

Upon launching the presentation, there are three handouts available for you to print or save for future reference: Educator Guide, Educator Glossary, and On Screen Notes.
To access the handouts, click on the slide notes and resources.

If you have any questions about this activity, please contact Brooke Hernandez in Indianapolis, IN, 317-871-0011 ext. 813 or via email at bhernandez@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High-speed internet connection
• Internet browser (current version) – Firefox, Safari, Chrome, or Explorer
  • Cookies and JavaScript must be enabled in the browser

21HT50146 – Hereditary Hemorrhagic Telangiectasia: Right Under Your Nose

June 1, 2022

5:00 PM Eastern, May 31, 2024
The estimated time to complete this activity is 60 minutes.

This online learning activity aims to enable the learner to gain knowledge and expertise regarding hereditary hemorrhagic telangiectasia (HHT), including inheritance and pathophysiology, screening guidelines, management, and the importance of the multidisciplinary approach in caring for these patients.

This online learning activity provides a detailed introduction to hereditary hemorrhagic telangiectasia (HHT) appropriate for an audience of multidisciplinary health care providers involved in the team-based care of patients with HHT. This overview includes information on the genetic inheritance and pathophysiology of HHT as well as the widely-used Curaçao diagnostic criteria to determine if a person has HHT, consensus screening guidelines for HHT management, and an explanation of the importance of a multidisciplinary approach to care of patients with HHT. This activity incorporates case scenarios and interactive questions to encourage active learning through application of the content.

This accredited continuing education activity is designed for physicians, physician assistants, nurse practitioners, nurses, and other multidisciplinary team members who care for patients with hereditary hemorrhagic telangiectasia.

At the conclusion of this activity, the participants should be better able to:

• Identify the Curaçao criteria for determining the likelihood of Hereditary Hemorrhagic Telangiectasia (HHT) in an undiagnosed individual
• Describe HHT genetics and pathophysiology
• Discuss the international consensus screening guidelines for HHT management
• Review management of epistaxis, iron deficiency, and pulmonary arteriovenous malformations (PAVMs) in HHT
• Explain the importance of an HHT Center-driven multidisciplinary approach in caring for patients with HHT

• Manjusha Kumar, MD
• Magdalena Lewandowska, MD

In order to receive continuing education credits, you must complete these steps prior to the activity expiration date.

• Read the Disclosure Information found in the To Dos section.
• Complete the learning activity
• Complete the evaluation
• Complete the post-test with a score of 70% or better
• Upon successful completion of the post-test your certificate of completion will be available to print or save

In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Indiana Hemophilia & Thrombosis Center. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIANS/PHYSICIAN ASSISTANTS
The University of Nebraska Medical Center designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSES/NURSE PRACTITIONERS
The University of Nebraska Medical Center designates this activity for 1.0 ANCC contact hours. This activity is provided for 0.15 contact hours related to pharmacotherapeutic content. Nurses should only claim credit for the actual time spent participating in the activity.

No commercial support was received for this activity.

If you have any questions about this activity, please contact Brooke Hernandez in Indianapolis, IN, 317-871-0011 ext. 813 or via email at bhernandez@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High-speed internet connection
• Internet browser (current version) – Firefox, Safari, Chrome, or Explorer
  • Cookies and JavaScript must be enabled in the browser

How Does Blood Clot?

The purpose of this activity is to enable the learner to improve understanding of and increase interest in the basic concepts involved in the complex coagulation process to ultimately improve patient care.

• Examine the coagulation process from the point of injury to clot resolution.
• Evaluate the platelet reaction step of normal hemostasis.
• Differentiate among the three coagulation pathways, including the various clotting factors that participate in hemostasis.

Nurses and other healthcare staff employed within or affiliated with the U.S. Hemophilia Treatment Center (HTC) network.

An animated module illustrating the coagulation cascade.

• Roshni Kulkarni, MD
• Usha M. Reddy, MD
• Bruce L. Evatt, MD

If you have any questions about this activity, please contact Brooke Hernandez in Indianapolis, IN, 317-871-0011 ext. 813, toll-free 877-256-8837, or via email at bhernandez@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High speed internet connection
• Any one Internet browser:
  • Firefox (Most Current Version)
  • Safari (Most Current Version)
  • Google Chrome (Most Current Version)
  • MS Internet Explorer (Most Current Version)
  • Cookies and JavaScript must be enabled in all browsers.
  • All browsers must have flash plug in installed and enabled.
• Cookies and JavaScript must be enabled in all browsers.
• All browsers must have flash plug in installed and enabled.
• Please note: This program requires FLASH PLAYER. If your computer does not have FLASH PLAYER, or does not allow such files to play, you will not be able to view this program. You will need to speak to your institution’s Information Technology department about enabling or installing FLASH PLAYER onto your computer.

21HT50949 - Hydroxyurea for the Treatment of Sickle Cell Disease

July 9, 2021

5:00 PM Eastern, July 8, 2022
The estimated time to complete this activity is 45 minutes.

The purpose of this activity is to enable learners to enhance his or her knowledge about the complications of sickle cell disease and the importance of hydroxyurea in reducing or preventing those complications; as well as to gain familiarity with the 2014 NHLBI guidelines concerning hydroxyurea treatment for adults living with sickle cell disease.

This online educational activity reviews the most common complications of sickle cell disease and introduces the most efficacious therapy currently available to treat and prevent these complications, hydroxyurea. The author discusses the rational behind hydroxyurea as a therapy, its effectiveness, and national prescribing guidelines.

This enduring material is intended for physicians, physician assistants, nurses, nurse practitioners, and other health care providers who treat persons with sickle cell disease and wish to improve their knowledge of hydroxyurea as a treatment for sickle cell disease as well as hydroxyurea prescribing practices, with the aim of improving health outcomes among persons with sickle cell disease.

At the conclusion of this enduring material, the participants should be better able to:

• Describe the most common complications of sickle cell disease, including acute chest syndrome, vaso-occlusive pain crisis, and stroke
• Discuss the rationale behind hydroxyurea as a treatment for sickle cell disease and its effectiveness at preventing sickle cell-related complications
• Analyze the mechanism of action, dosing, side effects, contraindications, and monitoring of hydroxyurea therapy for sickle cell disease
• Review the 2014 NHLBI Guidelines for hydroxyurea treatment for persons living with sickle cell disease

• Emily Riehm Meier, MD, MSHS

In order to receive continuing education credits, you must complete these steps prior to the activity expiration date.

• Read the Disclosure Information found in the To Dos section.
• Complete the learning activity
• Complete the evaluation
• Complete the post-test with a score of 70% or better
• Upon successful completion of the post-test your certificate of completion will be available to print or save

In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Indiana Hemophilia & Thrombosis Center. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Nebraska Medical Center designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The University of Nebraska Medical Center designates this activity for 0.75 ANCC contact hours. This activity is provided for 0.3 contact hours related to pharmacotherapeutic content. Nurses should only claim credit for the actual time spent participating in the activity.

No commercial support was received for this activity.

If you have any questions about this activity, please contact Brooke Hernandez in Indianapolis, IN, 317-871-0011 ext. 813 or via email at bhernandez@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High-speed internet connection
• Internet browser (current version) – Firefox, Safari, Chrome, or Explorer
  • Cookies and JavaScript must be enabled in the browser

20CE169 - Physical Therapy and Comprehensive Care

June 15, 2021

5:00 PM Eastern, June 16, 2023

The estimated time to complete this activity is 45 minutes.

The purpose of this module is to enable the learner to gain knowledge of the physical therapist’s role in providing comprehensive care at U.S. hemophilia treatment centers (HTCs), as well as the resources and opportunities available to physical therapists in the U.S. HTC network.

The activity begins with a brief description of the U.S. hemophilia treatment center (HTC) network and the comprehensive care model utilized at these centers. It then introduces the Physical Therapy Working Group (PTWG) of the National Hemophilia Foundation and resources available from this group, including recommendations on physical therapy evaluation elements as well as physical therapy treatment guidelines for bleeding disorder management. The activity also explains the physical therapist’s contribution to comprehensive care, including his or her role in helping patients select appropriate sports, physical activity, and employment.

This enduring material is intended for physical therapists, physical therapist assistants, nurses, nurse practitioners, and other health care providers who are involved with the federally recognized U.S. Hemophilia Treatment Center, or HTC, network or otherwise engaged in comprehensive care and/or physical therapy management of individuals with hemophilia and other bleeding disorders.

This activity assumes that the learner possesses fundamental knowledge of the musculoskeletal and neurological systems and a basic understanding of bleeding disorders and the comprehensive care model. Learners who do not meet these criteria may wish to complete the PartnersPRN activity, “Understanding Hemophilia”, prior to completion of this module on physical therapy and comprehensive care.

At the conclusion of this enduring material, the participants should be better able to:

• Discuss the history of the U.S. Hemophilia Treatment Center (HTC) network and the components of the multidisciplinary comprehensive care model employed by HTCs
• Explain the role of the Physical Therapy Working Group in the U.S. HTC network and resources available from this group
• Review funding opportunities available to physical therapists working in the U.S. HTC network
• Validate physical therapy as a key discipline in the multidisciplinary comprehensive care of people with bleeding disorders
• Discuss Physical Therapy Working Group guidelines for the management of bleeding disorders and the essential components of various team members’ roles within the comprehensive clinic as prescribed by the Physical Therapy Working Group
• Articulate the importance of sports and physical activity for persons with bleeding disorders and the physical therapist’s role in helping patients select appropriate activities
• Describe vocational considerations often discussed between the physical therapist and patient when treating persons with bleeding disorders

• Stacie Akins, PT, MHS
• Kimberly Baumann, MPT
• Sherry Herman-Hilker, PT, MS
• Jennifer Newman, MSPT

In order to receive continuing education credits, you must complete these steps prior to the activity expiration date.

• Read the Disclosure Information found in the To Dos section.
• Complete the learning activity
• Complete the evaluation
• Complete the post-test with a score of 70% or better
• Upon successful completion of the post-test your certificate of completion will be available to print or save

In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Indiana Hemophilia & Thrombosis Center on behalf of the Partners in Bleeding Disorders Education Program. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Nebraska Medical Center designates this activity for 0.75 ANCC contact hours. Nurses should only claim credit for the actual time spent participating in the activity.

This activity (CPTA #22-303) has been approved by the California Physical Therapy Association (CPTA) for 0.075 CEUs. While many states recognize continuing education credits from CPTA, please verify with your state Board that these credits are acceptable in your state. To learn more about CPTA, visit https://www.ccapta.org.

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

If you have any questions about this activity, please contact Brooke Hernandez in Indianapolis, IN, 317-871-0011 ext. 813 or via email at bhernandez@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High-speed internet connection
• Internet browser (current version) – Firefox, Safari, Chrome, or Explorer
  • Cookies and JavaScript must be enabled in the browser

20CE168 - Physical Therapy in the Care of Persons with Bleeding Disorders

June 15, 2021

5:00 PM Eastern, June 16, 2023

The estimated time to complete this activity is 90 minutes.

The purpose of this online learning module is to enable the learner to increase their knowledge on the musculoskeletal concerns, potential complications, and physical therapy management of bleeding disorders.

After providing a review of basic information about hemophilia and von Willebrand disease, this learning module describes signs and symptoms of hemophilic bleeding, the complications associated with recurrent bleeding, physical therapy interventions for acute and chronic musculoskeletal complications of hemophilia, and imaging techniques including X-ray, MRI, and musculoskeletal ultrasound, which may be used to assess musculoskeletal status in patients with bleeding disorders.

This enduring material is intended for physical therapists, physical therapist assistants, nurses, nurse practitioners, and other health care providers who are involved with the federally recognized U.S. Hemophilia Treatment Center, or HTC, network or otherwise engaged in comprehensive care and/or physical therapy management of individuals with hemophilia and other bleeding disorders.

This activity assumes that the learner possesses fundamental knowledge of the musculoskeletal and neurological systems and a basic understanding of bleeding disorders and the comprehensive care model. Learners who do not meet these criteria may wish to complete the PartnersPRN activity, "Understanding Hemophilia", prior to completion of this module on physical therapy and comprehensive care.

At the conclusion of this enduring material, the participants should be better able to:

• Summarize basic information on the clinical picture of hemophilia and von Willebrand disease
• Identify signs and symptoms of acute and chronic musculoskeletal bleeding including hemarthroses and muscle bleeding
• Evaluate the complications of recurrent hemarthroses including chronic synovitis, cartilage destruction, and hemophilic arthropathy
• Discuss physical therapy interventions for acute bleeding events and chronic musculoskeletal complications of bleeding disorders and how the multidisciplinary team can help implement these strategies to improve patient outcomes
• Differentiate imaging techniques and their use to assess musculoskeletal status in patients with bleeding disorders

• Stacie Akins, PT, MHS
• Kimberly Baumann, MPT
• Sherry Herman-Hilker, PT, MS
• Jennifer Newman, MSPT

In order to receive continuing education credits, you must complete these steps prior to the activity expiration date.

• Read the Disclosure Information found in the To Dos section.
• Complete the learning activity
• Complete the evaluation
• Complete the post-test with a score of 70% or better
• Upon successful completion of the post-test your certificate of completion will be available to print or save

In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Indiana Hemophilia & Thrombosis Center on behalf of the Partners in Bleeding Disorders Education Program. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Nebraska Medical Center designates this activity for 1.5 ANCC contact hours. Nurses should only claim credit for the actual time spent participating in the activity.

This activity (CPTA #22-302) has been approved by the California Physical Therapy Association (CPTA) for 0.15 CEUs. While many states recognize continuing education credits from CPTA, please verify with your state Board that these credits are acceptable in your state. To learn more about CPTA, visit https://www.ccapta.org.

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

If you have any questions about this activity, please contact Brooke Hernandez in Indianapolis, IN, 317-871-0011 ext. 813 or via email at bhernandez@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High-speed internet connection
• Internet browser (current version) – Firefox, Safari, Chrome, or Explorer
  • Cookies and JavaScript must be enabled in the browser

The Role of the Nurse in Hemophilia Care

The purpose of this module is to familiarize the learner with the critical role nurses play worldwide in the multidisciplinary care team.

• Examine the critical and variable role of the nurse in the care of people with hemophilia.
• Review the role responsibilities of the nurse related to education, care delivery, coordination of the healthcare team, and support of patient and family to learn to live with hemophilia.

While there are some responsibilities that are universal for all nurses, there is also a great deal of variation in the role and responsibilities of nurses in hemophilia care. This learning module describes those roles and responsibilities and some of the variation that may occur throughout the world.

• World Federation of Hemophilia

June 18, 2013

This module was created to describe the worldwide variation in the role and responsibilities of nurses in hemophilia care.

If you have any questions about this activity, please contact Brooke Hernandez in Indianapolis, IN, 317-871-0011 ext. 813 or via email at bhernandez@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High-speed internet connection
• Internet browser (current version) – Firefox, Safari, Chrome, or Explorer
  • Cookies and JavaScript must be enabled in the browser